Categories: All postsCannabis

HEXO gets price target raised to $12.25 at Beacon Securities

HEXO (HEXO Stock Quote, Chart TSX:HEXO) is getting a target price raise from analyst Russell Stanley of Beacon Securities, who rates the stock as a “Buy” (unchanged) with a target of $12.25 (was $11.00).

In a Tuesday update to clients, Stanley pointed to the cannabis company’s new NYSE listing and recent financing announcements as cause for the target raise.

Gatineau, Quebec’s HEXO announced in late January a marketed offering of 8.9 million shares at $6.50 per share, with net proceeds of approximately $54.7 million, to go towards general corporate purposes such as global growth initiatives and R&D.

As well, the company announced last week that it had entered into a syndicated credit facility co-led by CIBC and Bank of Montreal, with proceeds to go towards expansion of its cultivation and production facility in Gatineau as well as leasehold improvements at its Belleville, Ontario, facility.

As a result, Stanley has upped his multiple for HEXO from 20x to 23x his EV/2020 EBITDA estimate.

“We believe the multiple increase is justified following the recent listing on the NYSE, given that the handful of companies that trade there receive significant valuation premiums to their peers,” says Stanley. “Our 23x multiple is quite reasonable considering that it represents a 42 per cent discount to the 40x average amongst companies with a $1 billion-plus market capitalization, and an 67 per cent discount to the 70x average amongst companies that have a listing on a US exchange. Our new multiple is also in line with the broad peer group at 23x.”

Stanley estimates that HEXO will generate Adjusted EBITDA in fiscal 2019 of negative $3.7 million on revenue of $100.7 million and Adjusted EBITDA in fiscal 2020 of $117.2 million on a top line of $315.9 million. His new $12.25 target represented a projected 12-month return of 66 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: hexo
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago